前瞻性评估超声引导弥散光学断层成像作为乳腺活检女性辅助检查对BI-RADS评估的影响
前瞻性纳入61例拟行超声引导乳腺活检女性,活检前加做超声引导弥散光学断层成像(US-guided DOT),四位放射科医师先后给出常规影像BI-RADS和整合DOT后的BI-RADS评估。良性病变平均HbT 55.3±22.6 µM低于恶性肿瘤85.4±15.6 µM(p<.001),HbT阈值78.5 µM诊断恶性敏感度80%、特异度89%;整合DOT使良性病变可疑BI-RADS评估净减少23.5%,无癌症被降级为非可操作评估。
要点
- 良性病变平均HbT 55.3±22.6 µM,癌症85.4±15.6 µM(p<.001)。
- HbT阈值78.5 µM诊断恶性敏感度80%(12/15)、特异度89%(41/46)。
- 整合DOT使良性病变可疑BI-RADS评估净减少23.5%(31/132),无癌症被降级。
核心结论
- 整合US-guided DOT信息使良性病变的可疑BI-RADS评估减少23.5%;作者认为需更大规模研究并关注提高阅片者一致性。
研究设计与样本
- 前瞻性研究,2019年3月5日至2020年3月19日纳入61例拟行超声引导乳腺活检女性(平均年龄48岁),活检前即刻行US-guided DOT,获取平均最大总血红蛋白(HbT)空间图和定量HbT值;四位对组织病理学盲法的放射科医师先评估常规影像(CI)给出CI BI-RADS,再整合DOT信息给出CI&DOT BI-RADS;以组织病理学为参考标准,将BI-RADS ≥ 4A视为阳性。
诊断标准与关键数值
- 活检证实恶性15例(24.6%)、良性46例(75.4%);良性病变平均HbT 55.3±22.6 µM vs 癌症85.4±15.6 µM(p<.001);HbT阈值78.5 µM诊断恶性敏感度80%(12/15)、特异度89%(41/46)。
临床应用与阅片要点
- 共获得197对CI BI-RADS与CI&DOT BI-RADS评估;整合DOT使良性病变可疑(CI BI-RADS ≥ 4A)评估净减少23.5%(31/132,其中正确降级34次、错误升级3次),81次4A评估中38.3%(31/81)被适当降级,无癌症被降级为非可操作评估;阅片者间一致性CI BI-RADS kappa=0.48-0.53,CI&DOT BI-RADS kappa=0.28-0.44。
局限性
- 作者结论指出需更大规模研究,并关注提高阅片者一致性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
英文原文(摘要)· 点击展开
PURPOSE: To assess the impact of adjunctive ultrasound guided diffuse optical tomography (US-guided DOT) on BI-RADS assessment in women undergoing US-guided breast biopsy.
METHOD: This prospective study enrolled women referred for US-guided breast biopsy between 3/5/2019 and 3/19/2020. Participants underwent US-guided DOT immediately before biopsy. The US-guided DOT acquisition generated average maximum total hemoglobin (HbT) spatial maps and quantitative HbT values. Four radiologists blinded to histopathology assessed conventional imaging (CI) to assign a CI BI-RADS assessment and then integrated DOT information in assigning a CI&DOT BI-RADS assessment. HbT was compared between benign and malignant lesions using an ANOVA test and Tukey's test. Benign biopsies were tabulated, deeming BI-RADS ≥ 4A as positive. Reader agreement was assessed.
RESULTS: Among 61 included women (mean age 48 years), biopsy demonstrated 15 (24.6%) malignant and 46 (75.4%) benign lesions. Mean HbT was 55.3 ± 22.6 µM in benign lesions versus 85.4 ± 15.6 µM in cancers (p < .001). HbT threshold of 78.5 µM achieved sensitivity 80% (12/15) and specificity 89% (41/46) for malignancy. Across readers and patients, 197 pairs of CI BI-RADS and CI&DOT BI-RADS assessments were assigned. Adjunctive US-guided DOT achieved a net decrease in 23.5% (31/132) of suspicious (CI BI-RADS ≥ 4A) assessments of benign lesions (34 correct downgrades and 3 incorrect upgrades). 38.3% (31/81) of 4A assessments were appropriately downgraded. No cancer was downgraded to a non-actionable assessment. Interreader agreement analysis demonstrated kappa = 0.48-0.53 for CI BI-RADS and kappa = 0.28-0.44 for CI&DOT BI-RADS.
CONCLUSIONS: Integration of US-guided DOT information achieved a 23.5% reduction in suspicious BI-RADS assessments for benign lesions. Larger studies are warranted, with attention to improved reader agreement.
引用
- Poplack, Young, Hagemann, et al. Prospective assessment of adjunctive ultrasound-guided diffuse optical tomography in women undergoing breast biopsy: Impact on BI-RADS assessments. Eur J Radiol. 2021. PMID: 34801874. doi:10.1016/j.ejrad.2021.110029
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。